Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands		3 Months Ended
		Jun. 30, 2022	Jun. 30, 2021
Total revenues		$ 116,492	$ 41,063
Collaboration expense to Pfizer		18,016	5,261
Selling, general and administrative	[1]	79,032	61,212
Research and development		23,890	30,880
Total operating costs and expenses		125,853	98,385
Loss from operations		(9,361)	(57,322)
Interest expense	[2]	4,200	3,505
Interest income		(486)	(78)
Loss before income taxes		(13,075)	(60,749)
Income tax expense		8,164	911
Net loss and comprehensive loss		(21,239)	(61,660)
Net loss and comprehensive loss		$ (21,239)	$ (61,660)
Net loss per common share - basic (in USD per share)		$ (0.22)	$ (0.67)
Net loss per common share - diluted (in USD per share)		$ (0.22)	$ (0.67)
Weighted average common shares outstanding - basic (in shares)		95,388,294	91,637,151
Weighted average common shares outstanding - diluted (in shares)		95,388,294	91,637,151
Product revenue, net
Total revenues		$ 41,351	$ 11,554
Cost of revenue		4,915	1,032
Pfizer collaboration revenue
Total revenues		25,141	29,509
Accord license revenue
Total revenues		$ 50,000	$ 0

[1] Includes $1,163 and $1,323 of related party expense (inclusive of third-party pass-through costs) for the three months ended June 30, 2022 and 2021, respectively (see Note 5).

[2] Includes $3,632 and $2,904 of interest expense under the Sumitomo Pharma Loan Agreement for the three months ended June 30, 2022 and 2021, respectively (see Note 5).